- Home
- BNY vs ACHV Comparison
BNY vs ACHV Comparison
Compare BNY & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNY | ACHV |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.7M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BNY | ACHV |
|---|---|---|
| Price | $10.25 | $5.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 52.7K | ★ 660.3K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $1.84 |
| 52 Week High | $10.80 | $6.03 |
Technical Indicators
Market Signals| Indicator | BNY | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 69.73 |
| Support Level | $10.17 | $5.30 |
| Resistance Level | $10.31 | $5.72 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 62.50 | 86.38 |
Price Performance
Historical ComparisonAbout BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.